KrisstinaLorraineGowinDO

PubMed

• 27 citations
  Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial
  Krisstina L. Gowin, Tania Jain, Heidi E. Kosiorek, Raoul Tibes, John K. Camoriano
  Leukemia Research. 2017-03-01
• 35 citations
  Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis.
  Krisstina L. Gowin, Heidi E. Kosiorek, Amylou C. Dueck, John Mascarenhas, Ronald Hoffman
  Leukemia Research. 2017-09-01
• 12 citations
  Understanding the Mechanisms of Diet and Outcomes in Colon, Prostate, and Breast Cancer; Malignant Gliomas; and Cancer Patients on Immunotherapy.
  Shivtaj Mann, Manreet Sidhu, Krisstina Gowin
  Nutrients. 2020-07-26

Abstracts/Posters

• Integrative Medicine Modality Utilization and Impact on Quality of life in Cancer Patients
  Millstine, D and Gowin, K, ASCO survivorship symposium, 1/1/2016
• Limitation of fibrosis grade as diagnostic criteria for post polycythemia vera and essesntial thrombocytosis myelofibrosis
  Gowin KL, Verstovsek S, Gustad Daver N, Pemmaraju N, Valdez R, Kosieorek H, Dueck AC, Mesa RA, J Clin Oncol, 1/1/2015
• Interim Analysis of a Phase II Pilot Trial of Ruxolitinib combined with Danazol for Patients with Myelofibrosis Suffering from Anemia
  Gowin K, Dueck A, Mascarenhas J, Hoffman R, Nagi Reddy S, Reeder C, Camoriano J, Fauble V, Tibes R, Gano K, Ghurye V, Koenig P, Mesa R, 20th Congress of the European Hematology Association, Vienna, Austria, 1/1/2015
• Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis
  Gowin K, Dueck A, Mascarenhas J, Hoffman R, Nagi Reddy S, Reeder C, Camoriano J, Fauble V, Tibes R, Gano K, Ghurye V, Koenig P, Mesa R, Blood, 1/1/2015
• Pegylated Interferon Alpha-2a in 75 Patients with Myeloproliferative Neoplasms: A Single Center Experience
  Gowin, K., Jain, T., Kosiorek, H.,Tibes, R., Camoriano, J., Palmer, J. and Mesa, R, Blood, 1/1/2015
• Poor Correlation between DIPSS and Passamonti Prognostic Risk Scores for Post Polycythemia and Essential Thrombocytosis Myelofibrosis
  Coakley, M., Gowin, K., Kosiorek, H., and Mesa, R, Blood, 1/1/2015
• Integrative Medicine Modality Utilization and Impact on Quality of life in Cancer Patients
  Gowin, K, Chon, T, and Millstine, D, SIO, 1/1/2015
• Interim analysis of a phase ii pilot trial of ruxolitinib combined with danazol for patients with primary myelofibrosis (mf), post essential thrombocythemia-myelofibro...
  Gowin KL, Dueck AC, Mascarenhas JO, Hoffman R, Reeder CB, Camoriano J, Gano K, Ghurye V, Reddy SN, Koenig P, Fauble V, Tibes R, Mesa R, Blood, 1/6/2014
• The clinical phenotype of patients with primary myelofibrosis, polycythemia vera, and essential thrombocytosis whom only manifest who grade 1 fibrosis
  Gowin KL, Dueck AC, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Mesa RA, Blood, 1/6/2014
• A new prognostic model for response in myelofibrosis patients treated with jak2 inhibitors: a study from three US academic centers
  Kamal M, Boonstra PS, Weber AA, Perkins C, Gowin KL, Nguyen H, Mesa R, Gotlib JR, Talpaz M, Blood, 1/6/2014
• The hedgehog pathway as targetable vulnerability with 5-azacitidine in mds and aml
  Tibes R, Delman D, Hansen N, Gowin KL, Mesa R, Bogenberger JM, Blood, 1/6/2014
• Allogeneic transplant outcomes in mpn blast phase
  Gowin K, Cherington C, Slack J, Tibes R, Sproat L, Mesa R, Haematologica, 1/1/2014
• Patient Preference for Integrative Oncology Services: Living with Cancer 2014
  Millstine DM, Gowin K, Chon TY, Mayer AP, Bergstrom LR, 11th Annual Society of Integrative Medicine, 1/1/2014
• The hedgehog pathway as a targetable vulnerability with 5-azacitidine in MDS and AML
  Tibes R, Delman D, Hansen N, Gowin KL, Mesa R, Bogenberger JM, Blood, 1/1/2014
• Pegylated interferon alpha-2a in patients with myeloproliferative neoplasms (MPN): international experience in 115 cases
  Gowin K, Thapaliya P, Samuelson J, Harrison CN, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell CL, ..., Blood, 1/18/2011
• Patients with Polycythemia Vera and Essential Thrombocytosis have a higher risk of prior or concurrent tumors compared to patients with secondary thrombocytosis
  Gowin K, Piatek C, et al., Blood, 1/1/2010
• Join now to see all

Lectures

• Integrative Palliative Care 
  Mayo Clinic, Scottsdale, AZ - 1/1/2016
• Ruxolitinib for the treatment of polycythemia vera 
  1/1/2015
• Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis 
  1/1/2015
• Profile of pomalidomide and its potential in the treatment of myelofibrosis 
  1/1/2015
• Movement as Medicine 
  Mayo Clinic Cancer Center, Scottsdale, AZ - 1/1/2015
• Exercise in Cancer Care 
  Arizona State University, Tempe, AZ - 1/1/2015
• Management of thrombocythemia 
  1/29/2014
• The Cognitive Error Paradigm 
  1/1/2014
• Heavy Symptom Burden and Early Myelofibrosis in Polycythemia Vera and Essential Thrombocytosis 
  Phoenix, AZ - 1/1/2014
• Overview of Myelofibrosis, Current Treatment Options and Quality of Life Concerns 
  1/1/2014
• Progress in the Treatment of Myeloproliferative Neoplasms (MPN) 
  1/1/2014
• The Role of Exercise, Meditation, and Nutrition to Cope with MPN 
  1/1/2014
• Recognizing the Different Stages of Your MPN: Understanding Why Your Doctor May Need to Adjust Your Treatment Over Time 
  1/1/2014
• Helping Children and Teens Cope with MPN in the Family 
  1/1/2014
• Lymphadenopathy: Do we have B or P cells to blame? 
  Mayo Clinic Arizona, Phoenix, AZ - 1/1/2014
• The new landscape of therapy for myelofibrosis 
  1/1/2013
• Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis 
  1/1/2013
• Lessons on treating cancer: a caregiver's perspective 
  1/1/2013
• Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients 
  1/1/2012
• Essential Thrombocytosis 
  University of Southern California, Los Angeles, CA, 2010 - 1/1/2011
• A Rare Complication of Paracentesis 
  University of Southern California, Los Angeles, CA - 1/1/2009
• Join now to see all